Placebo Controlled Dose-Response Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia

Pfizer

Status and phase: Terminated; Phase 2

Conditions: Pain

Treatments: Drug: PD-217,014

Study type: Interventional

Funder types: Industry

Identifiers

NCT00159640

A4451006

Details and patient eligibility

About

The purpose of this study is to determine the effectiveness of PD-217,014 in the treatment of chronic pain following a shingles infection.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients must have pain present for more than 3 months after the healing of shingles skin rash.
• Patients at screening must have a score >=40 mm on the pain visual analogue scale.

Exclusion criteria

• Patients with poor renal function.
• Patients with other severe pain, that may impair the self-assessment of the pain due to shingles.
• Patients with abnormal electrocardiogram.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind